<DOC>
	<DOCNO>NCT00329095</DOCNO>
	<brief_summary>This open-label study patient currently use either topical prostaglandin sole ocular hypotensive medical therapy q.d. , topical prostaglandin plus adjunctive topical ocular hypotensive market product either q.d. , b.i.d . eye ( ) . Compliance measure two month participation .</brief_summary>
	<brief_title>An Evaluation Use Topical Ocular Hypotensive Medication Compliance</brief_title>
	<detailed_description>This open-label study patient currently use either topical prostaglandin sole ocular hypotensive medical therapy q.d. , topical prostaglandin plus adjunctive topical ocular hypotensive market product either q.d. , b.i.d . eye ( ) . Compliance measure two month participation .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Currently use one two topical ocular hypotensive medication Hypersensitivity component medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Compliance</keyword>
</DOC>